(1000+ posts)
* Spasov AA,
* Iezhitsa IN,
* Zhuravleva NV,
* Sinolitskii MK,
* Voronin SP.
Volgograd State Medical University; ZAO BIOAMID, Saratov.
It seems an established fact that magnesium (Mg) aspartate is effective in prophylaxis and adjuvant therapy of cardiac arrhythmia (e.g. prevention of toxic symptoms during therapy with digoxin). There are claims that L-aspartate salts are better delivery forms for cations such as Mg than D-aspartate salts, and Mg L-aspartate can be more beneficial in the treatment of several forms of primary Mg deficiency than Mg DL- and D-aspartate. Therefore, the purposes of the present work were to compare of antiarrhythmic action of Mg L-, D- and DL-aspartate stereoisomers using CaCl2- and aconitine-induced arrhythmia models in rats. It was found that intravenously administered Mg L-aspartate exhibited higher activity compared to Mg D- and DL-aspartate in calcium chloride and aconitine-induced arrhythmias. In rats with arrhythmias induced by calcium chloride Mg L-aspartate compared with Mg D-aspartate and Mg DL-aspartate produced greater decrease of incidence of arrhythmias, increase of time first arrhythmia onset, decrease of percentage of rats that died and increase of duration of life after onset of first arrhythmia. In rats with aconitine-induced arrhythmia Mg L-aspartate surpassed Mg D-aspartate and Mg DL-aspartate in parameters of acute toxicity (LD50), effective dose (ED50) and antiarrhythmic (therapeutic) ratio (LD50/ED50).
PMID: 16883267
1: Ann Noninvasive Electrocardiol. 2006 Apr;11(2):163-9.Click here to read Links
An evaluation of the impact of oral magnesium lactate on the corrected QT interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence.
* McBride BF,
* Min B,
* Kluger J,
* Guertin D,
* Henyan NN,
* Coleman CI,
* Silver BB,
* White CM.
School of Pharmacy, University of Connecticut, Storrs, USA.
BACKGROUND: Intravenous magnesium reduces the QTc interval of patients receiving ibutilide. Whether oral magnesium can reduce the QTc interval associated with oral sotalol and dofetilide is not known. This study was undertaken to evaluate the impact of oral magnesium on the QTc interval and whether an inherent intracellular magnesium deficiency exists among patients with arrhythmias. METHODS: Participants receiving sotalol or dofetilide for atrial or ventricular arrhythmias were randomized to receive magnesium l-lactate (504 mg elemental magnesium daily, Niche Pharmaceuticals, Roanoke, TX) or placebo for 48 hours. A 12-lead electrocardiogram (ECG) was obtained at baseline, 3 hours, and 51 hours after dosing to correspond to the Tmax after oral ingestion. The QTc interval was measured from the ECGs and compared between groups. Intracellular magnesium concentrations were determined by energy-dispersive x-ray analysis at baseline and 51 hours after dosing (Intracellular Diagnostics, Inc., Foster City, CA). RESULTS: The QTc interval reductions from baseline were greater in the magnesium group than placebo at 3 and 51 hours (P = 0.015 and P < 0.001, respectively). Sixty-three percent of patients (regardless of experimental group) had baseline intracellular magnesium concentrations below the normal reference range of 33.9-41.9 mEq/IU, with an average level of 32.6 +/- 2.2 mEq/IU. CONCLUSIONS: Oral magnesium l-lactate raises intracellular magnesium concentrations and lowers the QTc interval of patients receiving sotalol or dofetilide.
PMID: 16630091
